Evidence map›Paper›PMID 40495232›Full record

ArticleActa neuropathologica communications2025

Beyond the brain: early autonomic dysfunction in Alzheimer's disease.

Carmen Nanclares, Inés Colmena, Alicia Muñoz-Montero, Andrés M Baraibar, Ricardo de Pascual, Aneta Wojnicz, Ana Ruiz-Nuño, Antonio G García, Adrián Gironda-Martínez, Luis Gandía

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  3. Stress, stress systems, and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carmen Nanclares *Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain. carmen.nanclares@uam.es.
Inés ColmenaDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Madrid, Spain.
Alicia Muñoz-MonteroDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Madrid, Spain.
Andrés M BaraibarAchucarro Basque Center for Neuroscience, Leioa, Spain.
Ricardo de PascualDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain.
Aneta WojniczDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Madrid, Spain.
Ana Ruiz-NuñoDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Madrid, Spain.
Antonio G GarcíaDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Madrid, Spain.
Adrián Gironda-MartínezDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain.
Luis Gandía *Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain. luis.gandia@uam.es.

Funding

Ministerio de Ciencia e Innovación PID2020-117127RB-I00Spanish Ministry of Economy and Competitiveness SAF2016-78892-R
6 · The paper itself

Abstract

Alzheimer's disease (AD) is classically defined by central hallmarks such as amyloid-beta plaques, tau hyperphosphorylation, and synaptic failure. However, mounting evidence suggests that dysfunction outside the brain, particularly in the peripheral nervous system, may also play a significant role in disease progression. The adrenal medulla-a key regulator of systemic neurotransmission and stress response-has received little attention in this context. In this study, we investigated whether chromaffin cells (CCs) from the triple transgenic AD mouse model (3xTg) exhibit functional alterations that could contribute to peripheral neurochemical imbalance. Using electrophysiology, high-resolution amperometry, and neurotransmitter quantification, we identified early and progressive defects in CC function. Remarkably, even at two months of age-prior to cognitive decline-3xTg CCs showed impaired exocytosis, reduced vesicle release, and slower fusion pore kinetics. These changes were accompanied by diminished sodium (I

Indexed as

Adrenal MedullaAlzheimer DiseaseAutonomic Nervous System DiseasesBrainChromaffin CellsAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, TransgenicAlzheimer´s diseaseCatecholamine releaseChromaffin cellsElectrophysiologyNeuropsychiatric symptomsPeripheral dysfunction

Identifiers

PMID40495232
PMCPMC12150586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.